Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Agilent Technologies, Inc.NYSE: A
Accounts Receivables · Q3 FY2026 · quarter ended Jul 2026
Accounts receivables turns positive
Q3 FY2026 accounts receivables was $22M, compared with -$17M a year earlier. Trailing-twelve-month accounts receivables was -$89M. Over 3 fiscal years it compounded at -22.6% a year.
Context
- Accounts receivables amounted to 2.1% of revenue in FY2025, up 2.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $22M or moves back toward the trailing-twelve-month quarterly average of -$22.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (149M) USD
- Year-over-year change
- -2228.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (149M) | -2228.6% |
| FY2024 | 2024-10-31 | 7M | -94.7% |
| FY2023 | 2023-10-31 | 132M | +141.1% |
| FY2022 | 2022-10-31 | (321M) | -150.8% |
| FY2021 | 2021-10-31 | (128M) | — |
Accounts Receivables vs competitors
How A compares with its peers on the latest reported figures
- A's LTM Jul 2026 accounts receivables of $89M is the 3rd largest of the 9 companies compared; the peer median is $21.26M.
- Its year-over-year change of -14.4% is the 6th highest of 9, against a peer median of +100.0%.
- Accounts receivables amounts to 1.2% of revenue for A, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $880.37M | +846.5% | -26.2% | 19.0% | |
| LTM Sep 2026 | $174M | -19.4% | -23.2% | 0.7% | |
| LTM Jul 2026 | $89M | -14.4% | -22.6% | 1.2% | |
| LTM Jun 2026 | $45.54M | +114.9% | -17.8% | 1.1% | |
| LTM Jul 2026 | $35.21M | -46.7% | — | 1.2% | |
| LTM Jun 2026 | $8.1M | +148.2% | — | 0.3% | |
| LTM Jun 2026 | $7.31M | -67.7% | — | 0.3% | |
| LTM Sep 2026 | $0 | +100.0% | -0.3% | 0.0% | |
| LTM Jun 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding A) | $21.26M | +100.0% | -20.5% | 0.5% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | 1.21B | 1.25B | 1.24B | 1.29B | 434M |
| Depreciation & Amortization | 321M | 317M | 271M | 257M | 288M |
| Deferred Income Tax | 14M | 8M | (56M) | (64M) | (130M) |
| Stock-Based Compensation | 110M | 125M | 111M | 129M | 128M |
| Change in Working Capital | (102M) | (478M) | (116M) | 83M | (58M) |
| Accounts Receivables | (128M) | (321M) | 132M | 7M | (149M) |
| Inventory | (136M) | (248M) | (33M) | 34M | 45M |
| Accounts Payables | 64M | 121M | (171M) | 103M | 16M |
| Other Working Capital | 98M | (30M) | (44M) | (61M) | 30M |
| Other Non-Cash Items | (68M) | 86M | 322M | 57M | 897M |
| Operating Cash Flow | 1.49B | 1.31B | 1.77B | 1.75B | 1.56B |
| Capital Expenditures | (189M) | (291M) | (298M) | (378M) | (407M) |
| Acquisitions (Net) | (546M) | (52M) | (1M) | (862M) | 4M |
| Purchases of Investments | (22M) | (13M) | (8M) | (5M) | 0 |
| Sales of Investments | 12M | 22M | 5M | 0 | 8M |
| Other Investing Activities | (4M) | (4M) | (8M) | (13M) | (199M) |
| Investing Cash Flow | (749M) | (338M) | (310M) | (1.26B) | (394M) |
| Debt Repayment | 356M | 26M | (35M) | 637M | (41M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 72M |
| Common Stock Repurchased | (788M) | (1.14B) | (575M) | (1.15B) | (425M) |
| Dividends Paid | (236M) | (250M) | (265M) | (274M) | (282M) |
| Other Financing Activities | (28M) | 58M | (55M) | 35M | (39M) |
| Financing Cash Flow | (696M) | (1.37B) | (930M) | (752M) | (715M) |
| Effect of Forex Changes | 3M | (36M) | 5M | (2M) | 9M |
| Net Change in Cash | 43M | (434M) | 537M | (261M) | 459M |
| Free Cash Flow | 1.3B | 1.02B | 1.47B | 1.37B | 1.15B |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.